Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

Similar articles for PubMed (Select 15142875)

1.

Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation.

Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R.

Blood. 2004 Sep 1;104(5):1574-7. Epub 2004 May 13.

2.

Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.

Elhasid R, Krivoy N, Rowe JM, Sprecher E, Adler L, Elkin H, Efrati E.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1172-9. doi: 10.1002/pbc.22739.

PMID:
20672371
3.

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lemerle J, Gouyette A, Hartmann O.

Cancer Chemother Pharmacol. 1996;37(3):247-53.

PMID:
8529285
4.

Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.

Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, Boelens JJ, Guchelaar HJ.

Ther Drug Monit. 2008 Aug;30(4):504-10. doi: 10.1097/FTD.0b013e3181817428.

PMID:
18641537
5.

Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation.

Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R.

Drug Metab Dispos. 2001 Mar;29(3):264-7.

6.

Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.

Brice K, Valerie B, Claire G, Valerie M, Yves B, Gilles A, Nathalie B.

Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):135-43.

PMID:
17952879
7.

Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.

Kim I, Keam B, Lee KH, Kim JH, Oh SY, Ra EK, Yoon SS, Park SS, Kim CS, Park S, Hong YC, Kim BK.

Clin Transplant. 2007 Mar-Apr;21(2):207-13.

PMID:
17425746
8.

Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation.

Bredschneider M, Klein K, Mürdter TE, Marx C, Eichelbaum M, Nüssler AK, Neuhaus P, Zanger UM, Schwab M.

Clin Pharmacol Ther. 2002 Jun;71(6):479-87.

PMID:
12087351
9.

Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.

Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Théoret Y, Champagne MA, Krajinovic M.

Bone Marrow Transplant. 2010 Feb;45(2):261-7. doi: 10.1038/bmt.2009.143. Epub 2009 Jul 6.

PMID:
19584821
10.

Oral mucositis after bone marrow transplantation. A marker of treatment toxicity and predictor of hepatic veno-occlusive disease.

Wingard JR, Niehaus CS, Peterson DE, Jones RJ, Piantadosi S, Levin LS, Saral R, Santos GW.

Oral Surg Oral Med Oral Pathol. 1991 Oct;72(4):419-24.

PMID:
1923439
11.

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.

Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, Dai Q, Maire P, Jelliffe RW, Aulagner G.

Bone Marrow Transplant. 2001 Oct;28(8):743-51.

12.

Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.

Bouligand J, Le Maitre A, Valteau-Couanet D, Grill J, Drouard-Troalen L, Paci A, Hartmann O, Benhamou E, Vassal G.

Clin Pharmacol Ther. 2007 Oct;82(4):402-9. Epub 2007 Mar 28.

PMID:
17392724
13.

A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation.

Hahn T, Zhelnova E, Sucheston L, Demidova I, Savchenko V, Battiwalla M, Smiley SL, Ambrosone CB, McCarthy PL Jr.

Biol Blood Marrow Transplant. 2010 Jun;16(6):801-8. doi: 10.1016/j.bbmt.2010.01.001. Epub 2010 Jan 13.

14.

Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients.

Terakura S, Murata M, Nishida T, Emi N, Akatsuka Y, Morishima Y, Kodera Y, Naoe T.

Bone Marrow Transplant. 2006 Feb;37(4):381-6.

PMID:
16415899
15.

Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.

Kim SD, Lee JH, Hur EH, Lee JH, Kim DY, Lim SN, Choi Y, Lim HS, Bae KS, Noh GJ, Yun SC, Han SB, Lee KH.

Biol Blood Marrow Transplant. 2011 Aug;17(8):1222-30. doi: 10.1016/j.bbmt.2010.12.708. Epub 2011 Jan 6.

16.

Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome?

Sharda SV, Gulati S, Tripathi G, Jafar T, Kumar A, Sharma RK, Agrawal S.

Pediatr Nephrol. 2008 Nov;23(11):2001-6. doi: 10.1007/s00467-008-0883-1. Epub 2008 Jul 2.

PMID:
18594869
17.

Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.

Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.

Biol Blood Marrow Transplant. 2007 Mar;13(3):307-14.

18.

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.

Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C, Békassy A, Bielenstein M, Abdel-Rehim M, Georén S, Astner L.

Bone Marrow Transplant. 2000 May;25(9):915-24.

19.

Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.

Méresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, Lemerle J.

Bone Marrow Transplant. 1992 Aug;10(2):135-41.

PMID:
1525602
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk